CD27 is a TNF receptor super family member. It is expressed on the surface of T and B cells, and its binding with CD70 provides a co-stimulatory signal for T and B cell proliferation and for B cells producing immunoglobulins. Treating mice with a CD27 agonist antibody effectively enhanced the antitumor immune response for lymphoma and B16 melanoma, providing putative targets for tumor immunotherapy.
Protein Expression Analysis
Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hCD27 mice were analyzed by flow cytometry. Mouse CD27+ T cells were detectable in both WT C57BL/6 and homozygous B-hCD27 mice, while human CD27+ T cells were only detectable in homozygous B-hCD27 mice. This might be due to cross-recognition of hCD27 by anti- mCD27 antibodies.
Human CD27 mAb efficacy evaluation (MC38 cell line)
Murine colon cancer MC38 cells were subcutaneously implanted into homozygote B- hCD27 mice. Mice were divided into control and treatment groups (n=5) when the tumor size was approximately 150±50 mm3. Anti-hCD27 antibody significantly inhibited tumor growth in homozygote B-hCD27 mice, suggesting that the B-hCD27 mouse model is an effective tool for in vivo hCD27 antibody efficacy studies. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.
1. J Immunol. 2013 Oct 15;191(8):4174-83. doi: 10.4049/jimmunol.1300409. Epub 2013 Sep 11.
2. Blood. 2017 Jul 20;130(3):297-309. doi: 10.1182/blood-2016-12-756585. Epub 2017 May 11.
3. J Clin Oncol. 2017 Jun 20;35(18):2028-2036. doi: 10.1200/JCO.2016.70.1508. Epub 2017 May 2.
4. Immunotherapy. 2015;7(6):655-67. doi: 10.2217/imt.15.32. Epub 2015 Jun 22.